Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression

Siqi Wang1,2†, Jiaxin Sun1,2†, Raha M. Dastgheyb3 and Zhigang Li1*

1Scientific Research Centre, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, 2School of Medicine, Sun Yat-sen University, Shenzhen, China, 3School of Medicine, Johns Hopkins University, Baltimore, MD, United States

Immune cells are capable of influencing tumor progression in the tumor microenvironment (TME). Meanwhile, one mechanism by which tumor cells modulate immune cells function is through extracellular vesicles (EVs), which are cell-derived extracellular membrane vesicles. EVs can act as mediators of intercellular communication and can deliver nucleic acids, proteins, lipids, and other signaling molecules between cells. In recent years, studies have found that EVs play a crucial role in the communication between tumor cells and immune cells. Innate immunity is the first-line response of the immune system against tumor progression. Therefore, tumor cell-derived EVs (TDEVs) which modulate the functional change of innate immune cells serve important functions in the context of tumor progression. Emerging evidence has shown that TDEVs dually enhance or suppress innate immunity through various pathways. This review aims to summarize the influence of TDEVs on macrophages, dendritic cells, neutrophils, and natural killer cells. We also summarize their further effects on the progression of tumors, which may provide new ideas for developing novel tumor therapies targeting EVs.

KEYWORDS
macrophages, dendritic cells, neutrophils, natural killer cells, tumor-derived extracellular vesicles (TDEVs), tumor progression
1 Introduction

Extracellular vesicles (EVs) usually refer to a group of heterogeneous, cell-released, double-membraned 150-1000 nm structure vesicles (1, 2). To address the considerable discrepancy in the definitions of EV subtypes, the International Society for Extracellular Vesicles (ISEV) suggested using “small EVs” (sEVs) for EVs under 200nm and “medium/large EVs” (m/lEVs) for EVs larger than 200nm in the position paper published in 2018 (1). In this article, the term “EVs” represents all cell-derived extracellular membrane vesicles (though most studies investigate sEVs).

The biogenesis of EVs has been well characterized (3). It is known that EVs originate from endosomes that are divided into 3 parts: early endosomes, late endosomes, and recycling endosomes. Invaginated vesicles first form intraluminal vesicles and integrate their cargoes into early endosomes. This cargo can consist of proteins, nucleic acids, and lipids, etc. Endosomes that internalize cargo to be recycled are classified as “recycling endosomes”. The rest of the early endosomes are subsequently transformed into late endosomes (4), also called multi-vesicular bodies (MVBs) (5), while dividing their cargo into vesicles budding in the lumen of the late endosomes. Four multi-protein complexes, endosomal sorting complexes required for transport (ESCRT) 0, I, II, and III, are involved in this step. ESCRT-0 has an association with cargo gathering in a ubiquitin-dependent process. The recruitment of ESCRT-I and II promotes endosomal membrane budding and ESCRT III is essential for completing budding. If the cargoes are destined to be degraded, the late endosomes will fuse with lysosomes and their cargoes will be digested. Other late endosomes carrying cargoes will be transported into the plasma membrane, creating mature vesicles. These vesicles are released into the extracellular space upon fusion with the plasma membrane.

Some ESCRT-independent mechanisms of EV biogenesis have also been reported, such as the biogenesis mechanism related to tumor microenvironment (TME), angiogenesis, and metastasis. TME and angiogenesis are both crucial processes for tumor metastasis and are regulated by EVs. For example, by interacting with endothelial cells TDEVs display a capacity for promoting angiogenesis by transporting activated epidermal growth factor receptor (EGFR) (15). Moreover, EVs facilitate tumor metastasis by mediating extracellular matrix (ECM) remodeling. Matrix metalloproteinase (MMP) is the major performing protein in tissue remodeling (16) and EVs derived from glioblastoma tumors have been found to increase the expression of MMP14 RNA in microglia (17). It has been found that macrophage migration inhibitory factor (MIF) existing in EVs derived from pancreatic ductal adenocarcinoma (PDAC) formed a pre-metastatic niche in the liver thus advancing liver metastasis (18). In addition, TDEVs can deliver their cargo to cancer cells, immune cells, and stromal cells. TDEVs exert a dual effect on tumor development by inhibiting natural killer (NK) cytotoxicity, mediating neutrophil differentiation, and influencing dendritic cell function. In many cases, TDEVs stimulate the pro-inflammatory M2 phenotype differentiation of macrophages and create an immunosuppressive microenvironment in tumor tissue. PD-L1 packed in TDEVs prevents T cell activation and stops tumor cells from being identified and killed (19, 20). These studies all provide evidence that TDEVs are engaged in many processes of tumor progression that affect immune cell functions.

Innate immune cells can be divided into classical innate immune cells, innate lymphoid cells (ILCs), and innate-like lymphocytes (ILLs). Classical innate immune cells include monocytes, macrophages, conventional dendritic cells, granulocytes, and mast cells. Here we review the studies focusing on the modulatory functions of TDEVs on four kinds of innate immune cells: macrophages, dendritic cells, neutrophils of granulocytes, and natural killer (NK) of ILCs.

Macrophages are differentiated from monocytes that migrate to tissues and organs under the influence of chemokines such as monocyte chemoattractant protein 1 (MCP-1). Induced by pathogens or different types of cytokines in the local microenvironment, monocytes differentiate into two macrophage subsets with different functional properties: type-1 macrophage (M1, classically activated macrophage) and type-2 macrophage (M2, alternatively activated macrophage). Compared with M1, M2 commonly accounts for a larger proportion of TME in solid tumors and results in tumor immune escape (21). Macrophages perform a variety of important functions including: phagocytosis and sterilization, inflammatory reaction, antigen-presenting, and immune regulation. Thus, macrophages are fundamental for the development and progression of tumors.

Dendritic cells (DCs) are functionally sorted as conventional DCs (cDCs), plasmacytoid DCs (pDCs), and monocyte-derived inflammatory DCs (moDCs) while the last type only appears during inflammation (22). cDCs generally participate in immunity as antigen-presenting cells (APC), acting as a bridge between adaptive and innate immune systems. They are essential for the induction and maintenance of anti-tumor immunity. In
Depending on distinct environmental signals, tumor-infiltrating dendritic cells (TIDCs) display either anti-tumor or pro-tumor functions. In most cases, TIDCs exhibit a tolerogenic phenotype under the impact of immune-suppressive factors like vascular endothelial growth factor (VEGF), IL10, TGFβ, and prostaglandin E2 (PGE2), subduing Th1-activating ability while enhancing Th2 and Treg responding (24). As a special lineage of pDCs, pDCs are poor in antigen presentation and strong in IFN production. They contribute to tumor growth probably by activating Treg and forming an immune-subversive environment (25).

Neutrophils account for 70-80% of peripheral granulocytes. They possess a high generation rate of 1×10⁷ per minute but are short-lived (about 2-3 days in circulation). Within the cancer framework, neutrophils show N1 and N2 phenotypes, respectively acting as tumor suppressors and tumor promoters (22). Neutrophils are pro-inflammatory in the early stages of the tumor, but gradually display the immunosuppressive phenotype as the tumor progresses (26). They produce reactive oxygen/nitrogen species (ROS/RNS) to regulate inflammation, secret neutrophil elastase (NE) and MMP8/9 to accelerate invasion, release Oncostatin-M to encourage angiogenesis, and make PGE2 to promote tumor development (27).

NK cells are a subset of ILCs. There is a plethora of evidence indicating that NK receptor NKG2D assists the immune system in recognizing tumors. NK cells kill target cells and restrain primary tumor progression through various pathways including: antibody-dependent cell-mediated cytoxicity (ADCC), Fas/FasL pathway, perforin/granzyme pathway, and release of cytokines such as TNF (28). Nevertheless, the killing efficiency of NK is limited due to the presence of TGF-β in plasma of both solid and hematological tumors (29–31). TGF-β can reduce the expression of activating receptors (including NKG2D, Nkp30 and Nkp46) and upregulate the expression of the inhibitory receptor NKG2A (29–31).

In the following sections we discuss the diverse impacts of TDEVs on innate immune cells, which including macrophages, dendritic cells, neutrophils, and NK cells. We further summarize the effects of these regulated immune cells on tumor progression. We will focus on the cargoes of TDEVs which modulate innate immunity is the promising novel targets for tumor diagnosis and treatment.

### 2.1 TDEVs regulate the polarization of macrophage

It is well known that macrophages participate in innate immune responses (42). CD14 and CD68 are the characteristic surface markers of the human macrophages (43–46). Circulating monocytes become macrophages when infiltrating into tissues. Based on the expression of specific surface markers, monocyte-derived macrophages can be polarized and divided into two phenotypes including M1 and M2 (47). In humans, M1 macrophages specifically express CD64, CD86, MARCO, CXCL9, CXCL10, CXCL11, NOS2, and SOCS1 (46, 48–51) on the surface, while M2 macrophages are identified by expressing TGM2, CD23, CD163, CD206, ARG1 and CCL22 (44, 46, 48, 49, 52–54). M1 macrophages, also known as classically activated macrophages, are induced by Th1 cytokines such as IFN-γ, IL-1β, and LPS. They secrete pro-inflammatory cytokines and function as anti-tumor cells. M1 macrophages bear the antigen-presenting ability so that they can activate adaptive immunity and bring about tissue damage (39, 40, 42, 55, 56). Secreting inhibitory factors like IL-4, IL-10, and IL-13, M2 macrophages show pro-tumor activity by promoting local immunosuppression, angiogenesis, and metastasis (57, 58). Tumor-associated macrophages (TAM), taking up 50% of the host infiltrating cells in TME, are usually considered as M2
phenotype (59). Meanwhile, there are many subsets in between that have yet to be clarified, expressing both M1 and M2 markers (60–62). Studies have shown that the polarization of macrophages in TME towards M1 or M2 can be promoted by contents in TDEVs. In Table 1 we summarize previous studies that investigate TDEVs cargoes in regulating the polarization of the macrophage, including miRNAs, lncRNAs, circRNAs, and proteins.

| Cargo | Cancer type          | Mechanism                      | Polarization | References |
|-------|----------------------|--------------------------------|--------------|------------|
| miRNAs |                      |                                |              |            |
| miR-21 | Bladder cancer       | PI3K/AKT pathway               | M2           | (63)       |
| miR-25-3p, miR-130b-3p, miR-425-5p | CRC                              | PTEN/PI3K/AKT pathway          | M2           | (64)       |
| miR-301a-3p | Esophageal squamous cancer | PTEN/PI3K/AKT pathway          | M2           | (65)       |
| miR-222 | Adriamycin-resistant breast cancer | PTEN/PI3K/AKT pathway          | M2           | (66)       |
| miR-198-3p | Lung adenocarcinoma | Hippo pathway                  | M2           | (67)       |
| miR-423-3p | Cervical cancer      | Blocking the expression of CDK4 mRNA | M2           | (68)       |
| miR-21 | Hypoxic tumor cells, HNSCC, bladder cancer | –                             | M2           | (63, 69, 70) |
| miR-138-5p | Breast cancer | Inhibiting KDM6B expression     | M2           | (71)       |
| miR-770 | NSCLC                | Targeting MAP3K1               | M1           | (72)       |
| miR-130 | Breast cancer        | M2 macrophages reprogramming   | M1           | (73)       |
| miR-9  | HPV + HNSCC          | –                             | M1           | (74)       |
| lncRNAs |                      |                                |              |            |
| PCAT6  | NSCLC                | –                             | M2           | (75)       |
| ARSR   | Renal cell carcinoma | STST3 pathway                 | M2           | (76)       |
| HMMR-AS1 | HCC                  | MiR-147a/ARID3A axis           | M2           | (77)       |
| TP73-AS1 | Nasopharyngeal carcinoma | Binding with miR-342-3p      | M2           | (78)       |
| FGD5-AS1 | Pancreatic cancer    | STAT3/NF-κB pathway           | M2           | (79)       |
| ELFN1-AS1 | Osteosarcoma         | Sponging miR-138-5p and miR-1291 | M2           | (80)       |
| HCG18  | Gastric cancer       | Sponging miR-875-3p            | M2           | (81)       |
| circRNAs |                      |                                |              |            |
| hsa-circ-0048117 | Esophageal squamous cancer | Sponging miR-140               | M2           | (82)       |
| hsa_circ_0017252 | Gastric cancer    | Sponging miR-17-5p             | M2           | (83)       |
| circFARSA | NSCLC              | PTEN/PI3K/AKT pathway          | M2           | (84)       |
| circ_0001142 | Breast cancer       | Circ_0001142/miR-361-3p/PIK3CB pathway | M2           | (85)       |
| circPVT1 | Lung cancer         | MiR-124-3p/EZH2 axis           | M2           | (86)       |
| circSABF2 | Renal cell carcinoma | MiR-620/JAK1/STAT3 axis       | M2           | (87)       |
| circNEIL3 | Glioma              | Stabilizing IGF2BP3            | M2           | (88)       |
| protein |                      |                                |              |            |
| CSF-1, MCP-1/CCL2, EMA2/ AMP1 and LTA4H | Melanoma, skin squamous cell carcinoma and lung cancer | –             | M2           | (89)       |
| gp130   | Diffuse large B-cell lymphoma | STAT3 pathway                | M2           | (90)       |
| leptin  | Gallbladder cancer   | STAT3 pathway                 | M2           | (91)       |
| PTTPRO  | Breast cancer        | STAT3 pathway                 | M1           | (92)       |
| RNF126  | Nasopharyngeal carcinoma | PTEN/PI3K/AKT pathway         | M2           | (93)       |
| ANLN    | HNSCC                | PTEN/PI3K/AKT pathway          | M2           | (94)       |
| TIM-3   | Osteosarcoma         | Increases the expression of N-cadherin and Vimentin, decreases E-cadherin expression | M2           | (95)       |
| Melanoma | –                   | Up-regulate the expression of PD-L1 | M2           | (96)       |
| PD-L1   | Oral squamous cell carcinoma | –                          | M2           | (97)       |
| ICAM-1  | PDAC                 | –                             | M2           | (98)       |
| CXCL14  | Prostate cancer      | NF-κB pathway                 | M2           | (99, 100)  |
| oevβ6   | Prostate cancer      | –                             | M2           | (101)      |
| oevβ6 negative | Prostate cancer | –                              | M2           | (101)      |
2.1.1 miRNAs cargo in TDEVs

Tumor-derived miRNAs assist in M2 polarization, thereby enhancing tumor proliferation through intercellular dialogue. The PTEN/PI3K/AKT signaling pathway is a common mechanism by which miRNAs regulate macrophage polarization. In macrophages, activating the PI3K/AKT pathway leads to the activation of signal transducer and activator of transcription 3 (STAT3), which is crucial for the differentiation of macrophages into M2 phenotype (102, 103). For example, miR–21 is carried in human bladder T24 cancer cell-derived EVs and promotes macrophages to M2 polarization, which through inhibited PI3K/AKT dephosphorylation leads to increase STAT3 activation (63). The miRNAs (miR-25-3p, miR-130b-3p, miR-425-5p) transferred from colorectal cancer (CRC) to macrophages via EVs can enhance M2 polarization by adjusting PTEN through the activation of PI3K/Akt signaling pathway, which finally leads to tumor EMT, angiogenesis, and liver metastasis (64). The PTEN/PI3K/AKT signaling pathway is also the target of miR-30a-3p from esophageal squamous cancer cell-derived EVs (65) and miR-222 from Adriamycin-resistant MCF-7 breast cancer cell-derived EVs (66) to induce M2 polarization. Chen et al. have reported that highly enriched miR-19b-3p in lung adenocarcinoma-derived EVs promotes M2 polarization through the Hippo pathway (67). MiR-19b-3p targets PTPRD, suppresses the PTPRD-mediated dephosphorylation of STAT3, activates STAT3, and induces polarization (67). In addition, Yan et al. have found that cervical cancer cell-secreted EVs transported miR-423-3p to stimulate macrophage M2 polarization by blocking the expression of CDK4 mRNA (68).

EVs produced by hypoxic tumor cells are enclosed with miR–21 and promote the transformation from monocyte to M2-polarized macrophage, and form an immunosuppression environment in TME (69). The same effect of EV miR-21 has also been observed in head and neck squamous cell carcinoma (HNSCC) and bladder cancer (63, 70). Moreover, breast cancer cell-derived EVs carrying miR-138-5p suppress M1 polarization and upgrade M2 polarization through the inhibition of epigenetic factor lysine demethylase 6B (KDM6B) expression in a suspension coculture system comprising breast cancer cells and macrophages (71).

Notably, some miRNAs in EVs are capable of suppressing tumor progression. Non-small cell lung carcinoma (NSCLC) cell-derived extracellular vesicular miR-770 has been confirmed to inhibit M2 macrophage polarization by targeting MAP3K1, which in turn prevents tumor invasion (72). MiR-130 originating from breast cancer cells leads to a reprogramming from M2 macrophages to M1 macrophages while the upregulation of M1 specific markers and downregulation of M2 specific markers were tested. After reprogramming, the phagocytic function of macrophages is enhanced and the ability to metastasize is impaired (73). Furthermore, miR-9-enriched EVs derived from HPV + HNSCC promote M1 phenotype polarization and then improve the radiosensitivity of HNSCC (74).

2.1.2 lncRNAs cargo in TDEVs

lncRNAs are RNAs longer than 200 nucleotides with a relatively restricted protein-coding capacity (104). lncRNAs can promote M2 polarization in many ways. Chen et al. found that the knockdown of lncRNA PCAT6 could prevent its positive effect on M2 polarization and in turn accelerated NSCLC development (75). lncARSR-containing EVs derived from renal cell carcinoma achieve a similar effect via the STAT3 pathway (76). MiR-147a/ARID3A axis is activated under hypoxia condition by hepatocellular carcinoma (HCC)-derived EVs delivering lncRNA HMRR-AS1 (77). Mechanistically, HMMR-AS1 interacts with miR-147a to reduce ARID3A degradation while the PTEN/PI3K/AKT pathway is a common mechanism by which lncRNAs regulate macrophage polarization. In addition, lncRNA TP73-AS1 is highly expressed in nasopharyngeal carcinoma cell-derived EVs, which binds to miR-342-3p, promotes the M2 polarization of macrophages, and reinforces the motility and microtubule formation of macrophages (78). Furthermore, FGDS-AS1 enriched in pancreatic cancer cell-derived EVs mediates M2 polarization of macrophages by activating STAT3/NEB pathway (79).

Interestingly, previous studies have found that lncRNAs can bind with miRNA to remove them from circulation and then promote tumor growth. For example, lncRNA ELFN1-AS1 exists in osteosarcoma cell-derived EVs sponge miR-138-5p and miR-1291 to suppress the M2 polarization (80). The down-regulation of miR-875-3p reached by lncRNA HCG18 in gastric cancer cell-derived EVs facilitates the M2 polarization of macrophages (81).

In addition to regulating macrophage polarization, lncRNAs also cause chemoresistance. It has been confirmed that glioblastoma cell-derived extracellular vesicular Lnc-TALC induces temozolomide resistance by binding to ENO1 and phosphorylating p38 MAPK (105). LncRNA PART1 in glioblastoma cell-derived extracellular vesicular lnc-TALC promote tumor growth. For example, lncRNA ELFN1-AS1 exists in osteosarcoma cell-derived EVs sponge miR-138-5p and miR-1291 to suppress the M2 polarization (80). The down-regulation of miR-875-3p reached by lncRNA HCG18 in gastric cancer cell-derived EVs facilitates the M2 polarization of macrophages (81).

In addition to regulating macrophage polarization, lncRNAs also cause chemoresistance. It has been confirmed that glioblastoma cell-derived extracellular vesicular Lnc-TALC induces temozolomide resistance by binding to ENO1 and phosphorylating p38 MAPK (105). LncRNA PART1 in glioblastoma cell-derived extracellular vesicular lnc-TALC promotes tumor growth. For example, lncRNA ELFN1-AS1 exists in osteosarcoma cell-derived EVs sponge miR-138-5p and miR-1291 to suppress the M2 polarization (80). The down-regulation of miR-875-3p reached by lncRNA HCG18 in gastric cancer cell-derived EVs facilitates the M2 polarization of macrophages (81).

2.1.3 circRNAs cargo in TDEVs

Emerging studies indicate that circRNAs play a critical role in tumor-induced immune responses. CircRNAs sometimes serve as miRNA sponges, binding with them and removing them from circulation. For instance, esophageal squamous cancer cell-derived hasa-circ-0048117 is transmitted to macrophages, works as a miR-140 sponge, and mediates M2
Various signaling pathways are involved in the regulation of macrophage polarization. Tumor-derived circFARSA delivered by EVs regulates M2 polarization via PTEN/PI3K/AKT pathway to raise the metastatic potential of NSCLC (84). Circ_0001142 carried by breast cancer cell-released EVs influences macrophages' autophagy and polarization via circ_0001142/miR-361-3p/PIK3CB pathway (85). Circ_0001142, targeting PIK3CB, is capable of activating the PI3K/AKT - an effect that can be reversed by miR-361-3p (85). There are other signaling pathways circRNAs interfere with, resulting in M2 polarization and tumor progression, such as the miR-124-3p/EZH2 axis targeted by circPVT1 in EVs and miR-620/JAK1/STAT3 axis targeted by circSAFBR2 in EVs. Lung cancer cell-derived circPVT1 increases EZH2 expression by downregulating miR-124-3p expression so that macrophages are induced to polarize towards an M2-like phenotype (86). CircSAFBR2 in renal cell carcinoma cell-derived EVs functioned as a miR-620 sponge while JAK1 and STAT3 protein levels were tested markedly lower after co-culturing with miR-620 mimics (87). This correlates with the result that renal cell carcinoma cell-derived EVs induce macrophages to express a higher level of JAK1 and STAT3 protein, and miR-620 can prevent the JAK1 and STAT3 expression (87). In addition, circNEIL3 has been shown to contribute to tumor progression by stabilizing the oncogenic protein IGF2BP3, which is packaged by hnRNPA2B1 in glioma cells and transported to TAMs (88).

### 2.1.4 Protein cargo in TDEVs

Previous studies have found that proteins carried by TDEVs affect the polarization of macrophages in multiple ways. Park et al. reported a 3-4-fold increase of total EV-containing protein per cell under hypoxia conditions in melanoma cell lines (B16-F0 and A375), skin squamous cell carcinoma cell line (A431), and lung cancer cell lines (A549). Several abundant proteins such as CSF-1, MCP-1/CCL2, EMPA2/AIMP1, and LTA4H were detected in these EVs, which help in monocyte/macrophage recruitment and M2 polarization (89). Diffuse large B-cell lymphoma-derived EVs are enriched in gp130, which functions as the activator of the STAT3 signaling pathway to stimulate downstream targets like BCL2, SURVIVIN, and BAX to promote M2 polarization (90). Similarly, leptin existing in the EVs derived from gallbladder cancer boosts M2 macrophage polarization by activating the STAT3 signaling pathway as well (91). On the contrary, protein tyrosine phosphatase receptor type O (PTPRO) in EVs produced by breast cancer cells induces M1 polarization via inactivating the STAT signaling pathway and then inhibits tumor migration (92). In addition, nasopharyngeal carcinoma-derived EVs containing RNF126 induce the M2 polarization of macrophages and contribute to the invasion and metastasis of tumors. Yu et al. have demonstrated that RNF126 degrades PTEN and provokes the PI3K/AKT pathway to regulate macrophage polarization (93). Furthermore, HNSCC-derived EVs carrying Anillin, actin-binding protein (ANLN), induced M2 polarization of macrophages via PTEN/PI3K/AKT signaling pathway (94).

The T-cell immunoglobulin and mucin domain 3 (TIM-3), also known as HAVCR2, has been proved to express in activated Th1 cells, Tregs, macrophages, dendritic cells, NK cells, and tumor cells (107, 108). Cheng Z. et al. found that the TIM-3 in osteosarcoma cells-derived EVs promoted M2 polarization, tumor invasion, metastasis, and EMT (95). The underlying mechanism is that TIM-3 increases the expression of N-cadherin and Vimentin, but decreases that of E-cadherin in infiltrated monocytes (95). While Li et al. also demonstrated that TIM-3 enriched in melanoma cell-derived EVs facilitated M2 type differentiation but the mechanism remained elusive (96).

It is well known that the plasma membrane-associated receptors play an important role in the function of immune cells. The surface receptors can also be packed in TDEVs and exert an influence on macrophages in different manners. Yuan et al. revealed the mechanism underlying endoplasmic reticulum stress and tumor development. They found that endoplasmic reticulum stress led oral squamous cell carcinoma (OSCC) to produce EVs loaded with PD-L1 and up-regulate the expression of PD-L1 in macrophages, thus driving the M2 macrophage polarization (97). In addition, ICAM-1 enriched in PDAC-derived EVs binds to CD11c on the surface of macrophages. Besides inducing M2 phenotype differentiation, these EVs also up-regulate the secretion of pro-tumoral molecules like VEGF, MCP-1, IL-6, IL-1β, MMP-9, and TNFα in macrophages exposed (98). Moreover, evidence indicates that prostate cancer cell-derived EVs loading CXCL14 promotes M2 polarization through activating NF-κB signaling, which is a key regulator of macrophage function and tumor progression (99, 100). Prostate cancer cells release two kinds of EVs, including αvβ6 (a surface receptor of the integrin family) positive and negative expression EVs. The αvβ6-positive EVs promote the M2 type differentiation of peripheral blood mononuclear cells, while the negative ones prevent this effect (101).

### 2.2 TDEVs regulate the pro-inflammatory responses of macrophage

Macrophages can secrete pro-inflammatory factors to regulate fibrosis, metabolism, cellular debris, and T cell function directly or indirectly (109). For example, IL-6 released from macrophages dominantes in phosphorylating STAT3 and further promotes tumor growth and metastasis (110, 111). The level of pro-inflammatory cytokines can be up-regulated by TDEVs in gastric cancer, breast cancer, lung cancer, CRC, melanoma, and OSCC (112–119), leading to tumorigenesis and metastasis further. Inflammatory cytokines array showed that the expression of IL-6, CCL2, GCSF, and TNF-α was augmented by TDEVs, along with
the phosphorylation of transcription factor NF-κB, which indicates that TDEVs stimulate the secretion of pro-inflammatory cytokines via NF-κB signaling pathway in gastric cancer, lung cancer, breast cancer and melanoma (112–115, 120). Various components of EVs exerting regulatory effects are being studied. For example, palmitoylated proteins on the surface of EVs are identified as a key factor in binding with macrophage surface protein Toll-like receptor (TLR) 2 to further phosphorylate NF-κB and activate inflammatory responses (113) (Figure 1). In addition, miRNAs also play an important role in modulating pro-inflammatory cytokines release. Lung cancer-derived EVs transporting miR-16, -21, -29a bind to TLR7/8 on the surface of macrophages to elicit phosphorylated activation of NF-κB, which induces an increase in transcription of pro-inflammatory cytokines including IL-6 (115). Similarly, miR-25-3p in breast cancer-derived EVs binding with TLR7/8 increases the expression of IL-6 and phosphorylated NF-κB (116). Moreover, oncogenic miR-183-5p in breast cancer-derived EVs are engulfed by macrophages and downregulate target gene PPP2CA expression by combining with the binding sequence which leads to a decrease in dephosphorylation of p65, consequently promoting IL-1β, IL-6, and TNF-α secretion (121).

The STAT3 pathway is engaged in the modulation by TDEVs. EVs released by endoplasmic reticulum-stressed liver cancer cells upregulate IL-6, IL-10, and MCP-1 levels but downregulate TNF-α levels in macrophages with an increase in p-JAK2 and p-STAT3 (119). Gp130 (IL-6 receptor) is carried by TDEVs and interacts with macrophages to induce the phosphorylation and translocation of STAT3 to the nucleus, leading to an elevated expression of IL-6 and a shape of the pro-tumor cancer environment in several human breast cancer cell lines (MDA-MB231, MDA-MB-468, Hs578T, and MCF7) (118).

2.3 TDEVs regulate the anti-inflammatory responses of macrophage

TDEVs present a double-sided sword: they participate in activation of inflammatory responses, but they can downregulate
the expression of pro-inflammatory cytokines as well. HREV-positive EVs derived from two CRC cell lines (SK-CO1 and Caco-2) lead to a lower level of pro-inflammatory cytokine IL-1β and a higher level of anti-inflammatory cytokine IL-10 in the zebrafish model with a positive correlation between the concentration of HERV-positive EVs and anti-inflammatory responses (122). HNSCC-derived EVs down-regulate macrophage release of IL-1β, indicating that HNSCC-derived EVs block the activation of inflammatory pathways. TGF-β isoforms composition is hypothesized to be the key factor via inhibiting the NF-κB signaling pathway (123) (Figure 1). Previous studies have also indicated that miRNAs play an important role in the modulation of cytokines. Li J. et al. found that EVs treated under hypoxia and released by lung cancer cells down-regulate the expression of pro-inflammatory cytokines IL-6 and IL-1A through cargo containing miR101 while targeting CDK8 and SUB1 (124). Moreover, lncRNAs act as the mediator of cytokines secretion through TDEVs. Li X. et al. found that HCC-derived EVs containing lncRNA TUC339 were engulfed by macrophage (THP-1 cell) and downregulate the secretion of IL-1β and TNF-α (125).

2.4 TDEVs regulate the macrophages phagocytotic function

Macrophages, as phagocytes, engulf apoptotic cells and debris that trigger immune responses to exert an anti-tumor effect (109). Previous studies have indicated that the phagocytic activity of macrophages can be downregulated by TDEVs. EVs from metastatic osteosarcoma (K7M3 and DLM8) reduce the phagocytic function of alveolar macrophages via promoting TGF-β2 secretion, while there is no significant change in phagocytosis of macrophages taking up non-metastatic osteosarcoma (K7 and Dunn) -derived EVs (126). Along these same lines research conducted by Li X. and colleagues showed that HCC-derived EVs enriched in lncRNA TUC339 led to decreased FcγR-mediated phagocytosis in macrophages were found in (125). Furthermore, Gregory C.D. et al. found that apoptotic TDEVs contained phosphatidylserine (PtdSer) to bind with proteins such as T-cell immunoglobulin and mucin domain-4 (TIM-4), which had a positive relation to phagocytosis of apoptotic cells (127) (Figure 1). These studies shed light on the relationship between phagocytosis in macrophages and TDEVs, however, the specific mechanism is still unclear.

2.5 TDEVs modulate the macrophages migration

During cancer development, macrophages migrate out of circulation and into the tumor milieu, triggering inflammation and tumor metastasis (128). EVs released by PDAC elicit migration to the liver of bone marrow-derived cells including macrophages, which follows an elevated level of TGF-β released by Kupffer cells (18). Myeloma-derived EVs with serglycin engulfed by macrophages augment migration as compared with serglycin-null EVs (129). In addition, it is reported that EVs from breast cancer cells (MDA-MB-231) expressing high levels of signal-induced proliferation-associated 1 (SIPA1) promote the migration of macrophages to tumor tissue (130) (Figure 1). SIPA1 binds to the promoter of the target gene MYH9 to upregulate the transcription of MYH9, and the enrichment of myosin-9 in EVs contributes to macrophage migration (Figure 1).

3 Dendritic cells

Dendritic cells (DCs), derived from hematopoietic stem cells, are identified as a vital kind of innate immune cells. As APCs, DCs recognize and swallow pathogens, subsequently presenting to immune cells like T cells to activate immune responses, by corresponding receptors and co-stimulatory molecules on the surface (131). In addition, DCs also secrete cytokines and chemokines capable of modulating the microenvironment and tumor development. Various functions of DCs are regulated by TDEVs, and interestingly they are capable of causing both anti-tumor and pro-tumor effects under certain conditions. DCs are divided into three subsets, classical DC (cDC), plasmacytoid DC (pDC), and monocyte-derived DC (mo-DC) (132). The former two are derived from common dendritic cell progenitors (CDPs), and mo-DC are derived from monocytes. Mature DCs express a higher level of functional molecules including co-stimulatory molecules (CD40, CD80, CD86), MHC II, pro-inflammatory cytokines, and CCR7 comparing to immature DCs, via the stimulus with GM-CSF, IFN-γ, IL-4 and pathogens (133).

3.1 Anti-tumor effect of DCs on responses to TDEVs

TDEVs augment anti-tumor activity by promoting the function of DCs in many cancers like melanoma, HCC, and colon carcinoma (120, 134, 135). It has been found that tumor antigen (TA) carried by EVs are a key factor in this process. HCC cell-derived EVs inhibit tumor growth by transferring HCC antigens and antigenic chaperones to DCs, which induces cytolysis and increases IFN-γ expression but decreases IL-10 and TGF-β expression. Furthermore, DCs treated with HCC cell-derived EVs activate T-cell immunity by presenting antigens (135). Similarly, EVs containing tumor antigen ErbB2 promotes the activation of CD8+T cell by DC (136). Melanoma cell-derived EVs carrying tumor-associated antigens (TAAs) promote DCs to express maturation marker CD86 and raise the anti-tumor activity in
mouse models (137). In addition to whole-tumor antigens, MHC-I peptide complexes are also transferred to DCs by TDEVs in melanoma, resulting in the activation of cytotoxic T-lymphocytes (CTL) (138). The specific mechanism for this is still under investigation. The only known study to date is by Squadrito M.L. et al. who found that CRC-derived EVs internalized by DCs promoted the presentation of tumor antigens mediated by MHC-I, and extracellular vesicle-internalizing receptor (EVIR) played an important role in the binding and internalization of TDEVs by DCs (134) (Figure 2).

3.2 Immunosuppress effect of DCs on responses to TDEVs

A decrease in pro-inflammatory cytokine secretion but an increase in anti-inflammatory cytokines can be detected in DCs stimulated with TDEVs. In Lewis lung cancer (LLC) and breast cancer, surface markers including CD80, MHC-II, and CD86 are downregulated by TDEVs, indicating that DCs are immature. In addition, the cytokine expression in DCs is regulated by TDEVs as well. There is a decrease in TNF-α, IL-6, and IL-12, but an increase in Arginase I while the levels of IL-10 and IL-12p40 do not change significantly. In addition, chemokine receptor expression (which is essential for the migration of DCs) is inhibited by LLC cell-derived EVs (139). The expression of IL-6 is increased by TDEVs in breast cancer, lung cancer, and melanoma in various ways (140). HSP72 and HSP105 proteins on melanoma-derived EVs surface bind with TLR2 and TLR4 on DCs, causing the phosphorylation of ERK, JNK, p38, and NF-kB to induce expression of IL-6. IL-6 induces STAT phosphorylation to bind in the MMP9 promoter site and elevates the transcription of MMP9. Due to the function of reorganizing extracellular matrix by MMP9, tumor cells invade other organs. PGE2 carried by prostate cancer-derived EVs binds to receptors EP2/EP4 on DCs to upregulate the CD73 expression, while the adenosine monophosphate (AMP)-depends on expressions of IL-12 and TNF-α decrease subsequently (142). However, the underlying mechanism still needs further investigation.

Notably, microRNAs in TDEVs can interfere with the function of DCs. MiR-212-3p carried by pancreatic cancer
cell-derived EVs inhibited the expression of regulatory factor X-associated protein (RFXAP) to decrease MHC II on DCs and induce immune tolerance (143), while miR-203 induced the downregulation of TLR4 and cytokines in DCs such as TNF-α and IL-12 in pancreatic cancer (113). In head and neck cancer, TDEVs disrupt the maturation, viability, and migration of mono-CDs targeted by 133 miRNAs including miR-16, miR-23b, miR-24. CD80 and HLA-DR expression have been shown to exhibit a decrease in DCs after incubating with HNSCC cell-derived EVs (144) (Figure 2).

3.3 TDEVs modulate the differentiation of DCs

Wiekowskii E. et al. found that antigen-processing machinery (APM) components including MIB1, IMP7, Tapasin, and Calreticulin were downregulated in monocytes after stimulation with TDEVs, indicating impaired differentiation from monocytes to DCs (145). Surface proteins that demonstrate the maturation of DCs decrease with the stimulation of TDEVs in melanoma, lung cancer, renal cancer, breast cancer, and thymoma (139, 146–149). Expressions of markers such as CD40, α5 integrin, CD80, CD86, and HLA-DR are downregulated in monocyte-derived DCs after co-incubation with renal cancer derived-EVs carrying HLA-G, which can be inhibited by anti-HLA-G-antibody. This confirmed the negative-regulatory role of EVs with HLA-G in DCs differentiation (146) (Figure 2). Hendrik Gassmann and colleagues proposed a model where Ewing sarcoma-derived EVs carrying RNA and protein activate myeloid cell pathology and induce the secretion of pro-inflammatory cytokines such as IL-6, IL-8, and TNF, which modulates the differentiation of myeloid cells into semi-mature DCs and impairs T cell activation (150) (Figure 2). Moreover, the role of modulating differentiation by IL-6 was also examined in the breast cancer (148). Glioma-derived EVs down-regulate the expression of IL-12p70 in immortalized DCs, which orchestrates the maturation and differentiation of DCs (151).

4 Neutrophils

Neutrophils, abundant in circulation, are indispensable for an immune response due to their dual role of both affecting innate immunity and modulating adaptive immunity (152). The complicated function of neutrophils in the innate immune response includes forming neutrophil extracellular traps (NETs), polarization to a different state, phagocytosis, co-regulation with T cells, and so on. Interestingly, NETs are a double-sided sword in the immune response. On the one hand, they neutralize and ensnare microbiotics to against infection. On the other hand, they have adverse such as promoting thrombosis, tumor metastasis, and inflammation that causes organ and vascular damage (Figure 2). In addition, neutrophils also exert a dual effect on tumors by polarization to N1 or N2 phenotypes. In TME, stimulators including TGF-β and IFN-β respectively switch the phenotype of tumor-associated neutrophils (TANS) into N1 and N2 phenotypes (153) (Figure 2). The N1 phenotype shows an anti-tumor effect via enhancing apoptosis and secreting pro-inflammatory cytokines, while the N2 phenotype promotes tumor development and suppresses immune responses (154) (Figure 2).

4.1 TDEVs promote neutrophils NETs formation

TDEVs engulfed by neutrophils target NETs to promote thrombosis. A previous study has shown that tumor microparticles carrying tissue factor (TF) promoted cancer-associated deep vein thrombosis (DVT) initiation by adhering to NETs in a mouse model with pancreatic cancer (155). Ana C. Leal et al. showed that 4T1 murine breast tumor derived-EVs contribute to the prothrombotic state via inducing NETs formation by neutrophils stimulated by G-CSF in the murine breast cancer model (Figure 2). Moreover, there is a dose-dependent procoagulant property of 4T1 derived-EVs and this progress relies on the ability to recruit TDEVs by NETs (156). Exposure to TDEVs which bear gDNA induces TF activation in leukocytes, along with the upregulation of IL-8 (157). However, the function that TDEVs stimulated NETs promoting tumor growth is still under investigation.

4.2 TDEVs modulate neutrophils polarization

In addition to stimulating the formation of NETs, TDEVs play an important role in regulating the polarization of neutrophils. In CRC, TDEVs carrying oncogene circPACRGL promote the differentiation of neutrophils from N1 to N2 by regulating the miR-142-3p/miR-506-30-TGF-β1 axis (158). circRNA PACRGL swallowed by neutrophils binds to miR-142-30/miR-506-3p to inhibit the post-transcriptional control of mature mRNA and therefore TGF-β1 expression is downregulated, which induces neutrophils into the N2 phenotype (Figure 2). In addition, TDEVs induce neutrophil polarization to the N2 phenotype via the NF-κB pathway in gastric cancer and CRC (159, 160). Gastric cancer-cell derived EVs carrying high mobility group box-1 (HMGB1) bind with TLR or receptor for advanced glycation end products (RAGE) to activate NF-κB signaling, which induces the phosphorylation of downstream proteins including p65, STAT, and ERK and upregulates the expression of inflammatory factors such as IL-1β, IL-6, IL-8, OSM, and TNFα (Figure 2). Moreover, these
pro-tumor effects of EVs can be blocked by NF-κB inhibitors (159). In HCC, TDEVs regulate the phenotype of neutrophils into N2, but the exact mechanism needs further investigation (161). Taken together, these data suggest that TDEVs induce neutrophils to polarize into the pro-tumor state of the N2 phenotype in various signaling pathways.

4.3 TDEVs regulate neutrophils’ other functions

Other functions of neutrophils can also be regulated by TDEVs. For example, the lifespan of neutrophils was prolonged by EVs from CRC stem cells by modulating the expression of IL-1β via the NF-κB signaling axis. EVs with tri-phosphate RNAs, acting as pathogen-associated molecular pattern (PAMP) molecules, interact with PRRs and activate the NF-κB pathway with elevated expression of nuclear p65 and IL-1β [20]. In addition, PD-L1 on neutrophils is upregulated by gastric cancer cell-derived EVs, activated by HMGB1 via phosphorylating STAT3 and downstream molecules, which suppresses T-cell immunity to have a pro-tumor influence (162) (Figure 2). More changes in neutrophil function by TDEVs need further investigation.

5 NK cells

NK cells are a subset of type 1 ILCs with surface markers CD3 and CD19, but are CD56+ and CD16+. They originate from common lymphoid progenitor (CLP) cells in the bone marrow and are widely distributed in the blood, peripheral lymphoid tissue, liver, spleen, and other organs, accounting for 5-10% of peripheral blood mononuclear cells (163, 164). Activating and inhibitory receptors are co-expressed on the surface of NK cells, which can bind to MHC I molecules expressed on the surface of one’s cells. NK cells also express NKG2D and natural cytotoxicity receptors (NCR) (NKp30, NKp44, and NKp46) (165). They are activating receptors that do not interact with MHC I. Cancerous cells decrease the expression of MHC I and cause a loss of inhibitory receptor function, referred to as the “missing-self” mode. Meanwhile, tumor cells overexpress ligands of NKG2D and NCR, providing sufficient targets for activating receptors via the “induced-self” mode (166, 167). NK cells are activated through the above two modes and kill tumor cells by releasing perforin, granzyme, TNF-α, or FasL (168). In addition, as a group of type 1 ILCs, NK cells synthesize and secret IFN-γ to play a role in the anti-infection and immune regulation (169, 170).

In most cases, TDEVs exert an influence on NK cells through NKG2D ligands (MICA, MICB, ULBP-1, ULBP-2, or ULBP-3) existing on the surface of EVs. NKG2DLs downregulate NKG2Ds floating on the surface of NK cells and block cell activation, resulting in the damage of NK cytotoxicity (171, 172) (Figure 2). Besides NKG2DLs, TGF-β1 (173, 174) and some other immunosuppressive proteins (PD-L1, CD39, CD73, FasL, LAP-TGFβ, TRAIL, CTLA-4) (175-177) are common cargoes of TDEVs, which act the same way as NKG2DLs do (Figure 2). TGF-β in EVs has another mechanism to inhibit the activation of NK cells: interacting with its receptors on the surface of NK, activating the TGFβ-Smad2/3 pathway, and promoting the phosphorylation of Smad2/3 (178, 179). Furthermore, soluble ligand BAG6/BAT3 was found to exist in chronic lymphocytic leukemia patients’ blood (180). Once BAG6/BAT3 is expressed on the surface of EVs it interacts with the activating receptor NKp30 of NK cells and induces cell stress through the nSmase2-dependent pathway to suppress NK cytotoxicity (180).

Some cytokines in TDEVs have a dual effect on NK cells. For example, genetically modified myeloid leukemia cell line K562 expresses IL-15, IL-18, and 4-1BBL (TNFSF9) on the surface of its EVs. These proteins stimulate NK cells to proliferate and enhance the cytotoxicity of NK cells within 4 hours. However, as time goes by (48 hours), the cytokines reduce NK cytotoxicity via the inhibition of activated receptors (NKG2D, NKp44) and the promotion of inhibitory receptors (NKG2A) (181). Moloudizargari et al. also reported the bifacial effect of myeloma-derived-EVs on NK cells (181, 182).

The RNA component in TDEVs is also participating in regulating NK cells’ function. CRC-derived EVs containing lncRNA SNHG10 increase INHBC expression and then suppress the activation of NK (183). MiRNA-378a-3p in EVs is induced in tumors undergoing radiotherapy, leading to the reduction of granzyme-B secretion and loss of activity in NK cells (184). EVs from HCC cells deliver circUHRF and affect NK cells through three different ways to achieve immunosuppression and drug resistance. Firstly, decreasing IFN-γ and TNF-α secretion of NK cells. Secondly, degrading miR-449c-5p to foster the expression of TIM-3. Based on the fact that circRNAs usually work as miRNA sponges, studies indicated that circUHRF may inhibit miR-449c-5p to target each other in human NK-92 cells, thus impairing their function. Finally, there is a finding that the high levels of circUHRF in EVs can increase the connection with limited NK cell proportion and tumor infiltration (185).

6 Conclusions and perspectives

In recent years, EVs have become a popular topic in cancer and immunity research due to their complicated functions in regulating TME and their important role in mediating cell-to-cell communication (186, 187). Almost all cells including immune cells and cancer cells can generate EVs with common or specific cargoes which interact with recipient cells to further affect their functions and tumorigenesis (188, 189). In this review, we summarize the regulation of innate immune cells including macrophages, DCs, NK cells, and neutrophils by TDEVs (Figures 1, 2). Overall, TDEVs exert a dual
effect on immune responses and tumor development. For example, the secretion of pro-inflammatory cytokines by macrophages and cytotoxicity of NK cells is either up-regulated or down-regulated by TDEVs. Moreover, TDEVs induce macrophage polarization to different states (functions as pro-tumor or anti-tumor), further influencing tumorigenesis, metastasis, and so on. Previous studies have demonstrated that the specific function of TDEVs mainly depends on their bioactive cargoes and tumor stage. For instance, at the beginning of tumorigenesis, EVs stimulate TAM and up-regulate cytokines that benefit for angiogenesis and tumor metastasis. However, in the context of metastasis, anti-tumor responses such as cytotoxicity and phagocytosis are promoted by TDEVs. Based on these previous findings, the expression of innate immune cell markers and related molecules can be used as step-change indicators of diagnosis and prognosis in clinical treatment (190).

Various surface proteins and cargo components in TDEVs have been found to play an essential role in the regulation of macrophage polarization. Of the cargo components, most of the studies so far have been on miRNAs (Table 1). Other RNAs, proteins, and cytokines also target recipient cells to modulate their functions via direct binding with receptors or regulating corresponding gene expression. While the specific mechanism is still not completely known, NF-κB pathway and PTEN/PI3K/AKT pathways have been recognized as crucial signaling pathways in regulating immune responses. Therefore, key factor inhibitors can pharmacologically antagonize the effect of TDEVs. Moreover, there are also numerous studies concerning modulation of the formation, circulation, and absorption of TDEVs in anticancer therapies (191).

Although existing studies have provided many insights about the regulation of innate immunity by TDEVs, there are still many limitations. Firstly, the studies investigating TDEVs’ modulation of the function of innate immune cells like mast cells, eosinophils, and basophils remain inadequate. Secondly, more detailed mechanisms of TDEVs functions on innate immunity are still under investigation, and the results of these studies will be vital for identifying new cancer targets. Additionally, the majority of current studies are in vitro experiments, and more in vivo investigations are supposed to be conducted to better demonstrate the effects of TDEVs in cancer progression (192). TDEVs mediating intercellular communication between cancer and innate immune cells is a promising field, which can shed a spotlight on novel cancer therapies. We hope more investigations will be conducted to promote this progression.

Author contributions

ZL conceived and designed this review. SW and JS draft the manuscript. SW, JS, RD, and ZL revised and edited the manuscript. All authors approved the final version of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University (ZSQYBRJH0021 to ZL); Fundamental and Applied Basic Research Fund of Guangdong Province (2021A1515110512 to ZL); General project of Shenzhen Science and Technology Innovation Committee (JCY20210324134612035 to ZL); Fundamental Research Funds for the Central Universities, Sun Yat-sen University (22qntd3703 to ZL).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (Misev2018): A position statement of the international society for extracellular vesicles and update of the Misev2014 guidelines. J Extracell Vesicles (2018) 7(1):1335750. doi:10.1080/20013078.2018.1535750
2. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol (2014) 30:255–89. doi:10.1146/annurev-cellbio-101512-122326
3. Akers SC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol (2013) 113(1):1–11. doi:10.1007/s11060-013-1084-8
4. Stoorvogel W, Strouw GL, Geuze HJ, Oorschot V, Schwartz AL. Late endosomes derive from early endosomes by maturation. Cell (1991) 65(3):417–27. doi:10.1016/0092-8674(91)90459-c
5. Sotelo JR, Porter KR. An electron microscope study of the rat ovum. J Biophys Biochem Cytol (1959) 5(2):327–42. doi:10.1083/jcb.5.2.327
activated macrophages from gcm-csf and m-csf origin. Cell Immunol (2013) 281 (1-2):51–61. doi:10.1016/j.cellimm.2013.01.010
53. Rosser T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflammation (2015) 2015:816460. doi: 10.1155/2015/816460
54. Gordon EJ, Rao S, Pollard JW, Nutt SL, Lang RA, Harvey NL. Macrophages define dermal lymphatic vessel caliber during development by regulating lymphatic endothelial cell proliferation. Development (2010) 137(22):3899–910. doi:10.1242/dev.050021
55. Verreke FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. Human il-23-producing type 1 macrophages promote but il-10-producing type 2 macrophages subvert immunity to (Myco)Bacteria. Proc Nat Acad Sci U.S.A. (2004) 101(13):4560–5. doi: 10.1073/pnas.0400983101
56. Bouhelé MA, Derudas B, Rigamonti E, Dievert R, BroxeJ, Haulon S, et al. Psoriasis activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabol (2007) 6(2):137–43. doi:10.1016/j.cmet.2007.06.010
57. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumor-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2013) 6(3):146–58. doi:10.1038/nrclinonc.2013.5
58. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory microenvironment in cancer progression. The role of tumor-associated macrophages. Crit Rev Oncol Hematol (2008) 66(1-1):9. doi:10.1016/j.critrevonc.2007.07.004
59. ! Genard G, Wera AC, Huard C, Le Calve B, Pechnix S, Fattaccoli A, et al. Proton irradiation orchestrates macrophage reprogramming through nrf2 signaling. Cell Death Dis (2018) 9(7):728. doi:10.15382/cdd-18-0757-9
60. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep (2014) 6:13. doi: 10.12703/p/2014-01.006
61. Lin F, Yin HR, Li XY, Zhu GM, He WY, Guo X. Bladder cancer cells secreted exosomal Mr21 activates the Pten/Pk3 pathway in macrophages to promote cancer progression. Int J Oncol (2020) 56(1):151–64. doi:10.3892/ijo.2019.9433
62. Wang D, Wang X, Si M, Yang J, Sun S, Wu H, et al. Exosomal mir-21 activates the Pk3/Akt pathway in macrophages to promote cancer invasion. J Immunol Res (2022) 2022:9731049. doi:10.1155/2022/9731049
63. Chen WX, Wang DD, Zhu B, Zhang S, Xie H, Yan B, et al. Exosomal Circ0048117 facilitates M2 macrophage polarization acting as mir-140 sponge in esophageal squamous cell carcinoma. Onco Targets Ther (2020) 13:11883–97. doi:10.2147/OTT.S254192
64. Song J, Xu X, He S, Wang N, Bai Y, Li B, et al. Exosomal Hsa_Circ_0017252 attenuates the development of gastric cancer Via inhibiting macrophage M2 polarization. Int J Mol Sci (2021) 22(11):4999. doi:10.3390/ijms22114999
65. Chen T, Liu Y, Li C, Xu G, Ding C, Chen J, et al. Tumor-derived exosomal circarsa2 mediates M2 macrophage polarization Via the Pten/Pk3/Akt pathway to promote non-small cell lung cancer metastasis. Cancer Treat Res Commun (2021) 28:100412. doi:10.1016/j.ctarc.2021.100412
66. Chen T, Shi W, Wu H, Zhao Y, Zhang J, Dong F, et al. Endoplasmic reticulum stress promotes breast cancer cells to release exosomes Circ_c0001142 and induces M2 polarization of macrophages to regulate tumor progression. Pharmacol Res (2022) 177:10698. doi:10.1016/j.phr.2022.10698
67. Liu Y, Li L, Song X. Exosomal Cricpr derived from lung cancer promotes the progression of lung cancer by targeting mir-124-3p/Flk axis and regulating macrophage polarization. Cell Cycle (2021) 20(5):513–40. doi:10.1080/15384904.2021.2044997
68. Huang X, Wang J, Guan J, Zheng Z, Hao J, Sheng Z, et al. Exosomal Circzfs2b reshaping tumor environment to promote renal cell carcinoma progression by mediating M2 macrophage polarization. Front Oncol (2021) 12:88102. doi:10.3389/fonc.2021.88102
69. Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, et al. Ewsr1-induced Circneil3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization Via stabilizing Lgf2/bpi. Mol Cancer (2021) 21(1):16. doi:10.1186/s13046-021-00745-9
70. Park JE, Dutta B, Wu S, Gupta N, Tan CF, Low JK, et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene (2019) 38(25):5158–73. doi:10.1038/s41388-019-0782-x
71. Ling HY, Yang Z, Wang PJ, Sun Y, Ju SG, Li J, et al. Distinct large b-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype Via Gp130/stat3 signaling pathway. Cell Biochem Biophys (2022) 35:120977. doi:10.1007/s12013-022-00739-8
72. Zhao S, Liu Y, He L, Li Y, Lin K, Kang Q, et al. Gallbladder cancer cell-derived exosome- mediated transfer of leptin promotes cell invasion and migration by modulating Stat1-mediated M2 macrophage polarization. J Cell Biochem (2020) 122(22):2894–906. doi:10.1002/jcb.29406
73. Dong H, Xue J, Jiang Y, Li K, Yang P, et al. Tumor-derived exosomal protein tyrosine phosphatase receptor type O polarizes macrophages to suppress...
breast tumor cell invasion and migration. Front Cell Dev Biol (2021) 9703537.

93. Yu C, Xue B, Li J, Zhang Q. Tumor cell-derived exosome Rnf126 affects the immune microenvironment and promotes nasopharyngeal carcinoma progression by regulating pten ubiquitination. Apoptosis (2022) 27(7):890–905. doi: 10.1007/s10495-022-01276-9

94. Guo C, Mao X, Wang X, Guo L, An C, Zhang C, et al. Alternatively spliced anih isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma. Cell Death Dis (2021) 12(8):764. doi: 10.3389/fcell.2021.012425

95. Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3. Arch Med Res (2022) 52(2):200–10. doi: 10.1016/j.arcmed.2020.10.018

96. Li X, Liu Y, Yang L, Jang Y, Qian T. Tim-3 shuttled by Mv3 cells-secreted exosomes inhibits Cdk4+ T cell immune function and induces macrophage M2 polarization to promote the growth and metastasis of melanoma cells. Transl Oncol (2022) 18:103344. doi: 10.1016/j.tranon.2021.103344

97. Yuan Y, Jiao P, Wang Z, Chen M, Du H, Xu L, et al. Endoplasmic reticulum stress promotes the release of exosomal pd-l1 from head and neck cancer cells and facilitates M2 macrophage polarization. Cell Commun Signal (2022) 20(1):12. doi: 10.1186/s12964-021-00810-2

98. Linton SS, Abraham T, Liao J, Clawson GA, Butler PJ, Fox T, et al. Tumor-promoting effects of pancreatic cancer cell exosomes on thp-1 Derived macrophages. PLoS One (2018) 13(11):e0206759. doi: 10.1371/journal.pone.0206759

99. Tian HY, Liang Q, Shi Z, Hao H. Exosomal Cxcl14 contributes to M2 macrophage polarization through nf-kappab signaling in prostate cancer. Oncol Med Cells Longev (2022) 2022:756696. doi: 10.1155/2022/756696

100. Biswas SK, Lewis CE. Nf-kappab as a central regulator of macrophage function in tumors. J Leukoc Biol (2010) 88(5):877–84. doi: 10.1189/jlb.0310153

101. Li H, Bowler N, Harshyne LA, Craig Hooper D, Krishin SR, Kurtoglu S, et al. Exosomal alphabeta2 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol (2018) 70:20–35. doi: 10.1016/j.matbio.2018.03.009

102. Tacke RS, Tossello-Trapont A, Nguyen, V Mullins DW, Hahn YS. Extracellular hepatitis C virus core protein activates Stat3 in human Monocytes/macrophages. J Biol Chem (2011) 286(12):10847–55. doi: 10.1074/jbc.M110.175652

103. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 115(5):1155–66. doi: 10.1172/JCI31422

104. Deng R, Zhang B, Tan B, Lin N. Long non-coding rnas as the regulators and targets of macrophage M2 polarization. Life Sci (2021) 266:118895. doi: 10.1016/j.lfs.2021.118895

105. Li Z, Meng X, Wu P, Zha C, Han B, Li L, et al. Glioblastoma cell-derived Incrna-containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol Res (2019) 7(12):1383–99. doi: 10.1158/2326-0666.CIR-19-0125

106. Kang M, Ren M, Li Y, Fu Y, Deng M, Li C. Exosome-mediated transfer of Incra Part1 induces ge inflammatory cytokine production in metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology (2020) 9(17):1747677. doi: 10.2147/oncotarget.d25084-9

107. Wing JB, Tay C, Sakaguchi S. Control of regulatory T cells by Co-signal function in tumors. Nat Rev Immunol (2015) 16(4):343–5. doi: 10.1038/nri.2015.83

108. Ferrari L, Cafora M, Rota F, Hoxha M, Iodice S, Tarantini L, et al. Extracellular vesicles released by colorectal cancer cells modulate innate immune response in zebrafish model. The possible role of human endogenous retroviruses. Int J Mol Sci (2019) 20(15):3669. doi: 10.3390/ijms20153669

109. Bottino L, Rodrigues-Junior DM, Farias IS, Branco LM, Iyer NG, de Albuquerque GE, et al. Extracellular vesicles derived from head and neck squamous cells carcinoma inhibit Nlrp3 inflammasomes. Curr Res Immunol (2022) 1:1. doi:10.1007/s43670-021-00005-4

110. Li J, Xu P, Wu D, Guan M, Wang X, Lu Y, et al. Hypoxic stress suppresses lung tumor-secreted exosomal Mir191 to activate macrophages and induce inflammation. Cell Death Dis (2012) 3(6):776. doi: 10.3389/fcell.2012.00430-x

111. Li X, Lei Y, Wu M, Li N. Regulation of macrophage activation and polarization by hcc-derived exosomal Incrna Tuc339. Int J Mol Sci (2018) 19(10):2958. doi: 10.3390/ijms19102958

112. Wolf-Demken K, Gordon N, Kleinerman ES. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology (2020) 9(1):1747677. doi: 10.2147/oncotarget.d25084-9

113. Gregory CD, Dransfield I. Apoptotic tumor cell-derived extracellular vesicles as important regulators of the onco-regenerative niche. Front Immunol (2018) 9:1111. doi: 10.3389/fimmu.2018.01111

114. Gao WJ, Liu JX, Liu MN, Yao YD, Liu QZ, Liu L, et al. Macrophage 3d migration: A potential therapeutic target for inflammation and deleterious progression in diseases. Pharmacol Res (2016) 107:1.50563. doi: 10.1016/j.phrs.2016.107:50563

115. Parunokhatham A, Bandari SK, Chandrashekar DS, Jones RI, Lee HC, Weber DM, et al. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget (2017) 8(43):53723–32. doi: 10.18632/oncotarget.20564

116. Feng L, Weng J, Yao C, Wang R, Wang N, Zhang Y, et al. Extracellular vesicles derived from Sipa1(High) breast cancer cells enhance macrophage infiltration and cancer metastasis through myosin-9. Biol (Basel) (2022) 11(4):543. doi: 10.3390/biol11040543

117. Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol (2015) 238:1–80. doi: 10.1016/brcmb.2015.12.008

118. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol (2015) 16(4):343–53. doi: 10.1038/ni.3132

119. Squadrillo ML, Cianciaruso C, Hansel SK, De Palma M. Evir: Chimeric antigen receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat Methods (2018) 15(3):183–6. doi:10.1038/nmeth.4579
Cancer Res

transforming growth factor-Beta-Mediated suppressive activity on T lymphocytes.
doi: 10.1186/s12885-015-2025-z

differentiation of bone marrow dendritic cells.

exosomes educate dendritic cells to promote tumor metastasis

lines disrupt dendritic cells function and match plasma microRNAs.

Dos Santos Dias B, et al. Extracellular vesicles cargo from head and neck cancer cell

mediated neutrophil polarization and therapeutic implications.

increases the incidence of deep vein thrombosis in mice.

Tissue factor expressed by circulating cancer cell-derived microparticles drastically

modifies tumor metastasis.

Wang et al. 10.3389/fimmu.2017.01847

mediated neutrophil polarization and therapeutic implications.

Cancers (Basel)

2162402X.2017.1362527

Grange C, Tapparo M, Tritta S, Deregibus MC, Battaglia A, Gontero P,

Asti E, Montermini L, Lee TH, Karatzas

Hsp72/Hsp105-A2b receptor signaling. Angiogenesis (2020) 23(4):599–610. doi: 10.1007/s10432-020-0097-8

142. Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z. Dominant

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

143. Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen J, et al. Pancreatic cancer-

151. Sheybani ND, Batts AJ, Mathew AS, Thim EA, Price RJ. Focused

ultrasound hyperthermia augments release of glioma-derived extracellular

and function.

journal.pone.0022517

hypersensitivity model.

PloS One

doi:10.1002/hep.28549

–

9. doi:10.1111/jth.13002

–

72. doi:10.1002/hep.28549

–

88. doi:10.18632/oncotarget.4924

–

8. doi:10.1371/journal.pone.0016899

–

54. doi:10.1158/1078-0432.CCR-16-2819

–

4. doi:10.1158/1078-0432.CCR-16-2819

–

25. doi:10.18632/oncotarget.6013

–

93. doi:10.1111/imm.12921

–

6.e2.

–

76:60

–

Exp Hematol

–

6.e2.

Exp Hematol

–

90:2081. doi:10.3390/cells0802081

–

936(7051):709–13. doi: 10.1038/nature3847

–

11. doi:10.1111/j.1365-8358.2005.01255-x

–

111(1):18534. doi:10.1186/s13155-011-9775-3

–

376(2):258–65. doi: 10.1136/immunology-2007-05275.x

–

42. doi:10.1385/IR:36:1:247

–

29. doi:10.1111/j.1365-8358.2005.01255-x

–

54. doi:10.1158/1078-0432.CCR-16-2819

–

2567.2007.02573.x

–

25. doi:10.1007/s12027-014-0699-4

–

121(2):258–65. doi: 10.1136/immunology-2007-05275.x

–

136. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

–

143. Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen J, et al. Pancreatic cancer-

–

156. Leal AC, Mizurini DM, Gomes T, Rochael NC, Saraiva EM, Dias MS, et al.

–

53. doi:10.1002/jimm.213002

–

23. doi:10.1002/jimm.213002

–

133. (2011) 64(2):456

–

72. doi:10.1002/hep.28549

–

22. doi:10.1097/01.jem.0000290310

–

11. doi:10.1111/j.1365-8358.2005.01255-x

–

111(1):18534. doi:10.1186/s13155-011-9775-3

–

54. doi:10.1158/1078-0432.CCR-16-2819

–

2567.2007.02573.x

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

–

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

–

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

–

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

–

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.

–

137. Ito T, Sugiura K, Hasegawa A, Ouchi W, Yoshimoto T, Mizoguchi I, et al.

–

136. Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, et al.
178. Zhao J, Schlosser HA, Wang Z, Qin J, Li J, Popp F, et al. Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers (Basel) (2019) 11(6):874. doi: 10.3390/cancers11060874

179. Xia Y, Zhang Q, Zhou Q, Zhao Y, Liu N, Li T, et al. Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway. Oncotarget (2017) 8(23):37783-95. doi: 10.18632/oncotarget.16354

180. Reiners KS, Topolar D, Henke A, Simhadri VR, Keoslerl, Sauer M, et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 121(18):3658-65. doi: 10.1182/blood-2013-04-76606

181. Li Q, Huang Q, Huyan T, Wang Y, Huang Q, Shi J. Bifacial effects of engineering tumour cell-derived exosomes on human natural killer cells. Exp Cell Res (2018) 363(2):141–50. doi: 10.1016/j.yexcr.2017.12.005

182. Mohosudizargari M, Redegeld F, Asghari MH, Mosaffa N, Mortaz E. Long-chain polyunsaturated omega-3 fatty acids reduce multiple myeloma exosome-mediated suppression of NK cell cytotoxicity. Nutrients (2020) 12(9):2747. doi: 10.3390/nu12092747

183. Huang Y, Luo Y, Ou W, Wang Y, Dong D, Peng X, et al. Exosomal lincRNA Snhg10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating inibec. Cancer Cell Int (2021) 21(1):528. doi: 10.1186/s12935-021-00222-1

184. Briand J, Garnier D, Nadaradjane A, Clement-Colmou K, Potiron V, Supiot S, et al. Radiotherapy-induced overexpression of exosomal mirna-378a-3p in cancer cells limits natural killer cells cytotoxicity. Epigenomics (2020) 12(5):397–408. doi: 10.2217/epi-2019-0193

185. Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, Shi GM, et al. Cancer cell-derived exosomal Ccl13 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer (2020) 19(1):110. doi: 10.1186/s12943-020-01222-5

186. Ho J, Chauwing L, St Clair DK. Extracellular vesicles and cancer therapy: Insights into the role of oxidative stress. Antioxidants (Basel) (2022) 11(6):1194. doi: 10.3390/antiox11061194

187. Li Y, Zhao W, Wang Y, Wang H, Liu S. Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment. J Nanobiotechnol (2022) 20(1):288. doi: 10.1186/s12951-022-01382-0

188. Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: Cell-to-Cell mediators of metastasis. Cancer Cell (2016) 30(6):836–48. doi: 10.1016/j.cell.2016.10.009

189. Lipinski S, Tiemann K. Extracellular vesicles and their role in the spatial and temporal expansion of tumor-immune interactions. Int J Mol Sci (2021) 22(7). doi: 10.3390/ijms22073374

190. Catoni C, Di Paolo V, Rossi E, Quintieri L, Zambardi R. Cell-secreted vesicles: Novel opportunities in cancer diagnosis, monitoring and treatment. Diagnostics (Basel) (2021) 11(6):1118. doi: 10.3390/diagnostics11061118

191. Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular vesicles in cancer. J Clin Invest (2016) 126(4):1163–72. doi: 10.1172/JCI81130

192. Khawar MB, Abbasi MH, Siddique Z, Arif A, Sheikh N. An update on novel therapeutic warfronts of extracellular vesicles (Evs) in cancer treatment: Where we are standing right now and where to go in the future. Oxid Med Cell Longev (2019) 2019:9702562. doi: 10.1155/2019/9702562
| Abbreviation | Definition |
|--------------|------------|
| AMP          | adenosine monophosphate |
| ADC-C        | antibody-dependent cell-mediated cytotoxicity |
| APC          | antigen-presenting cells |
| APM          | antigen-processing machinery |
| CRC          | colorectal cancer |
| CDP          | common dendritic cell progenitors |
| CLP cells    | common lymphoid progenitor cells |
| cDCs         | conventional DCs |
| CTL          | cytotoxic T lymphocyte |
| DVT          | deep vein thrombosis |
| DCs          | dendritic cells |
| ESCRT        | endosomal sorting complex required for transport |
| EGFR         | epidermal growth factor receptor |
| EMT          | epithelial-mesenchymal transition |
| ECM          | extracellular matrix |
| EVIR         | extracellular vesicle-internalizing receptor |
| EVs          | extracellular vesicles |
| FGF          | fibroblast growth factor |
| HCC          | hepatocellular carcinoma |
| HMGB1        | high mobility group box-1 |
| HNSCC        | head and neck squamous cell carcinoma |
| ILCs         | innate lymphoid cells |
| ILLs         | innate-like lymphocytes |
| ISEV         | International Society for Extracellular Vesicles |
| EVs          | large EVs |
| KDM6B        | lysine demethylase 6B |
| LLC          | Lewis lung cancer |
| MIF          | macrophage migration inhibitory factor |
| MMP          | matrix metalloproteinase |
| mEVs         | medium EVs |
| MCP-1        | monocyte chemoattractant protein 1 |
| moDCs        | monocyte-derived inflammatory DCs |
| MVBs         | multi-vesicular bodies |
| NCR          | natural cytotoxicity receptor |
| NK           | natural killer |
| NE           | neutrophil elastase |
| NETs         | neutrophil extracellular traps |
| NSCLC        | non-small cell lung cancer |
| OSCC         | oral squamous cell carcinoma |
| PDAC         | pancreatic ductal adenocarcinoma |
| PAMP         | pathogen-associated molecular pattern |
| PRRs         | pattern recognition receptors |
| pDCs         | plasmacytoid DCs |
| PDGF         | platelet-derived growth factor |
| PGE2         | prostaglandin E2 |
| PTPRO        | protein tyrosine phosphatase receptor type O |
| ROS/RNS      | reactive oxygen/nitrogen species |
| RAGE         | receptor for advanced glycation end products |
| RFXAP        | regulatory factor X-associated protein |
| SIPA1        | signal-induced proliferation-associated 1 |
| sEVs         | small EVs |
| TIM-3        | T cell immunoglobulin and mucin domain 3 |
| TIM-4        | T cell immunoglobulin and mucin domain-4 |
| TLR          | Toll-like receptor |
| TA           | tumor antigen |
| TME          | tumor microenvironment |
| TAM          | tumor-associated macrophages |
| TANs         | tumor-associated neutrophils |
| TDEVs        | tumor-derived EVs |
| TIDC         | tumor infiltrating dendritic cells |
| VEGF         | vascular endothelial growth factor |